DGIdb - METHYLDOPA Drug Record

LEDERDOPA
MK-351
METALPHA 500
DOPAMET
MEDOMET
METHYLDOPA HYDRATE
BAYER-1440L
METALPHA 250
ALDOMET
J9.247I
NSC-169916
METHYLDOPA
ALPHA-METHYLDOPA
METHYLDOPA (LEVOROTATORY)
METHYLDOPA SESQUIHYDRATE
NOVOMEDOPA
SEMBRINA
METHYL DOPA
METHOPLAIN
DOPEGYT
L-(-)-3-(3,4-DIHYDROXYPHENYL)-2-METHYL-ALANINE
L-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE
ALDORIL D30
NU-MEDOPA TAB 250MG
PRESOLISIN
METHYLDOPA 500 TAB 500MG
NU-MEDOPA
NOVO-MEDOPA TAB 500MG
L(-)-ALPHA-METHYLALANINE
ALPHA-METHYLDOPA (VAN)
BECANTA
(S)-(-)-ALPHA-METHYLDOPA
MEDOPA
METHYLDOPA ANHYDROUS
NOVO-MEDOPA TAB 125MG
2-METHYL-3-(3,4-DIHYDROXYPHENYL)ALANINE
A-METHYL-L-DOPA
APO METHYLDOPA TAB 125MG
(-)-A-METHYLDOPA
METHYLDOPA 125 TAB 125MG
NU-MEDOPA TAB 125MG
L-ALPHA-METHYLDOPA
ALPHA-METHYL-L-DOPA
ALDORIL 25
AMD
(-)-ALPHA-METHYLDOPA
(-)-METHYLDOPA
L-2-AMINO-2-METHYL-3-(3,4-DIHYDROXYPHENYL)PROPIONIC ACID
Α-METHYL DOPA
APO METHYLDOPA TAB 500MG
ALDORIL 15
APO METHYLDOPA TAB 250MG
BAYER 1440 L
3-HYDROXY-ALPHA-METHYL-L-TYROSINE
DOPAMETHYPERPAX
L-A-METHYLDOPA
(S)-(-)-A-METHYLDOPA
ALPHA-METHYL-L-3,4-DIHYDROXYPHENYLALANINE
(2S)-2-AMINO-3-(3,4-DIHYDROXYPHENYL)-2-METHYLPROPANOIC ACID
MEDOPAL
A-METHYLDOPA (VAN)
METHYLDOPATE HCL
ALDOCLOR-150
SEDOMETIL
ALPHAMETHYLDOPA
ALDOCLOR-250
L-(-)-ALPHA-METHYL-BETA-(3,4-DIHYDROXYPHENYL)ALANINE
MEDOPREN
L-(-)-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE
METHYL-L-DOPA
L(-)-A-METHYLALANINE
GROSPISK
HYPOLAG
METHYLDOPATE
L-METHYL DOPA
ALDORIL®
NU-MEDOPA TAB 500MG
ALPHA-METHYL DOPA
Α-METHYL-L-DOPA
APO-METHYLDOPA
ALPHA-METHYLDIHYDROXYPHENYLALANINE
ALDOMET®
BAYPRESOL
L-(A-MD)
L(-)-BETA-(3,4-DIHYDROXYPHENYL)-ALPHA-METHYLALANINE
ALDOMETIL
L-(ALPHA-MD)
ALPHA MEDOPA
L-Α-METHYL-3,4-DIHYDROXYPHENYLALANINE
DOPATEC
3,4-DIHYDROXY-2-METHYLPHENYLALANINE (ACD/NAME 4.0)
L-(-)-A-METHYL-A-METHYL-ALDOMIN
HYPERPAX
A-METHYL DOPA
LEVO-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE
PRESINOL
DOPAMET®
L-(-)-ALPHA-METHYL-ALPHA-METHYL-ALDOMIN
ALDORIL D50
NOVO-MEDOPA TAB 250MG
ANHYDROUS METHYLDOPA
L-ALPHA-METHYL-3,4-DIHYDROXYPHENYLALANINE
METHYLDOPA 250 TAB
A-METHYL-L-3,4-DIHYDROXYPHENYLALANINE
ALPHA-METHYL-BETA-(3,4-DIHYDROXYPHENYL)-L-ALANINE
L-A-METHYL-(3, 4-DIHYDROXYPHENYL)ALANINE
L-ALPHA-METHYL-(3, 4-DIHYDROXYPHENYL)ALANINE
rxcui:6876
chemidplus:555-30-6
chembl:CHEMBL459
drugbank:00968
pubchem.compound:38853
rxcui:1545996

Year of Approval	1962
Drug Class	antihypertensive agents
Drug Categories	adrenergic alpha-agonists
FDA Approval	1962
Drug Class	small molecule
Drug Indications	Antihypertensive Agents
Drug Categories	catechols
Drug Categories	agents causing muscle toxicity
Drug Categories	antihypertensive agents indicated for hypertension
Drug Categories	aromatic l-amino acid decarboxylase inhibitors
Drug Categories	benzene derivatives
Drug Categories	central alpha-2 adrenergic agonist
Drug Categories	central alpha-agonists
Drug Categories	drugs that are mainly renally excreted
Drug Categories	enzyme inhibitors
Drug Categories	phenols
Drug Groups	investigational
Drug Categories	agents for treatment of hemorrhoids and anal fissures for topical use
Drug Categories	copper absorption inhibitor
Drug Categories	diet, food, and nutrition
Drug Categories	elements
Drug Categories	food
Drug Categories	food and beverages
Drug Categories	growth substances
Drug Categories	laxatives
Drug Categories	metal cations
Drug Categories	metal divalent cations
Drug Categories	metals
Drug Categories	metals, heavy
Drug Categories	micronutrients
Drug Categories	minerals
Drug Categories	physiological phenomena
Drug Categories	replacement preparations
Drug Categories	trace elements
Drug Categories	transition elements
Drug Categories	vasoprotectives
Drug Categories	zinc compounds
Drug Groups	nutraceutical
Drug Categories	acids
Drug Categories	acids, noncarboxylic
Drug Categories	anions
Drug Categories	chlorine compounds
Drug Categories	electrolytes
Drug Categories	ions
Drug Categories	magnetic resonance contrast activity
Drug Categories	paramagnetic contrast agent
Drug Categories	sulfur acids
Drug Categories	sulfur compounds
Drug Categories	sulfuric acids
Drug Categories	cell-mediated immunity
Drug Categories	chromium
Drug Categories	increased histamine release
Drug Categories	standardized chemical allergen

(7 More Sources)

Kawasaki, 1997, [Centrally acting sympathetic inhibitors for therapy of patients with hypertension]., Nippon Rinsho
van Zwieten, New central mediators as targets of centrally acting antihypertensive drugs., Clin. Exp. Hypertens.
Head, 1999, Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents., Ann. N. Y. Acad. Sci.
van Zwieten, 1992, Development and trends in the drug treatment of essential hypertension., J Hypertens Suppl
Sica, 2007, Centrally acting antihypertensive agents: an update., J Clin Hypertens (Greenwich)
Velliquette et al., 2003, Contrasting metabolic effects of antihypertensive agents., J. Pharmacol. Exp. Ther.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
SOURKES, 1954, Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine., Arch. Biochem. Biophys.
Zeqiraj E et al., 2015, Higher-Order Assembly of BRCC36-KIAA0157 Is Required for DUB Activity and Biological Function., Mol Cell
Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci
Krishnan U et al., 2006, Novel mutations that enhance or repress the aggregation potential of SOD1., Mol Cell Biochem
Blom AM et al., 2003, Effects of zinc on factor I cofactor activity of C4b-binding protein and factor H., Arch Biochem Biophys
Song C et al., 2013, Crystal structure and functional mechanism of a human antimicrobial membrane channel., Proc Natl Acad Sci U S A
Marx G, 1988, Zinc binding to fibrinogen and fibrin., Arch Biochem Biophys
She YM et al., 2003, Identification of metal-binding proteins in human hepatoma lines by immobilized metal affinity chromatography and mass spectrometry., Mol Cell Proteomics
Mayer MC et al., 2014, Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization., J Biol Chem
Rasimas JJ et al., 2003, Effects of zinc occupancy on human O6-alkylguanine-DNA alkyltransferase., Biochemistry
Chen Z et al., 2006, Identification of residues critical for Cu2+-mediated inhibition of glycine alpha1 receptors., Neuropharmacology
Martens E et al., 2007, A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains., Biochim Biophys Acta
Gilman JG et al., 1978, The oxygen-linked zinc-binding site of human haemoglobin., Biochem J
Jannetto PJ et al., 2001, Cytochrome b(5) plays a key role in human microsomal chromium(VI) reduction., Toxicology
Wang Y et al., 2007, Structure of the human p53 core domain in the absence of DNA., Acta Crystallogr D Biol Crystallogr
Brodersen DE et al., 1999, Zinc-binding site of an S100 protein revealed. Two crystal structures of Ca2+-bound human psoriasin (S100A7) in the Zn2+-loaded and Zn2+-free states., Biochemistry
Stasser JP et al., 2005, Cysteine-to-serine mutants of the human copper chaperone for superoxide dismutase reveal a copper cluster at a domain III dimer interface., Biochemistry
Hnia K et al., 2007, ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site., Biochem J
Meloni G et al., 2007, Redox silencing of copper in metal-linked neurodegenerative disorders: reaction of Zn7metallothionein-3 with Cu2+ ions., J Biol Chem
Bossak K et al., 2015, Unusual Zn(II) Affinities of Zinc Fingers of Poly(ADP-ribose)Polymerase 1 (PARP-1) Nuclear Protein., Chem Res Toxicol
Massiah MA et al., 2006, Solution structure of the RBCC/TRIM B-box1 domain of human MID1: B-box with a RING., J Mol Biol
Suzuki H et al., 2008, Crystallization and X-ray diffraction analysis of N-terminally truncated human ALG-2., Acta Crystallogr Sect F Struct Biol Cryst Commun
Sutherland DE et al., 2012, Single domain metallothioneins: supermetalation of human MT 1a., J Am Chem Soc
Bhuiyan MP et al., 2006, Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases., Bioorg Med Chem
Nestler M et al., 2006, The zinc containing pro-apoptotic protein siva interacts with the peroxisomal membrane protein pmp22., Mol Cell Biochem
Conner SH et al., 2006, TAK1-binding protein 1 is a pseudophosphatase., Biochem J
Røjkaer R et al., 1997, Partial identification of the Zn2+-binding sites in factor XII and its activation derivatives., Eur J Biochem
Kostic M et al., 2006, Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53., J Mol Biol
Jonsson M et al., 2006, Truncated semenogelin I binds zinc and is cleaved by prostate-specific antigen., J Androl
Soundar S et al., 2006, Identification of Mn2+-binding aspartates from alpha, beta, and gamma subunits of human NAD-dependent isocitrate dehydrogenase., J Biol Chem
Vogl T et al., 2006, Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations., Biochim Biophys Acta
Bitto et al., 2007, Structure of aspartoacylase, the brain enzyme impaired in Canavan disease., Proc. Natl. Acad. Sci. U.S.A.
Herga S et al., 2006, Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease., FEBS Lett
Smit V et al., 1992, Human interleukin-3 contains a discontinuous zinc binding domain., Biochem Biophys Res Commun
Nan R et al., 2011, Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration., J Mol Biol
Payne JC et al., 2003, Spectroscopic determination of the binding affinity of zinc to the DNA-binding domains of nuclear hormone receptors., Biochemistry
Golub MS et al., 1996, Aluminum alters iron and manganese uptake and regulation of surface transferrin receptors in primary rat oligodendrocyte cultures., Brain Res
Yang F et al., 2007, High-yield expression in Escherichia coli of soluble human MT2A with native functions., Protein Expr Purif
Palumaa P et al., 2005, Metal binding of metallothionein-3 versus metallothionein-2: lower affinity and higher plasticity., Biochim Biophys Acta
Kothinti R et al., 2010, Zinc finger transcription factor Zn3-Sp1 reactions with Cd2+., Chem Res Toxicol
Koch M et al., 2007, Implications on zinc binding to S100A2., Biochim Biophys Acta
Zakharian TY et al., 2008, Synthesis of (2S)-2-amino-7,8-epoxyoctanoic acid and structure of its metal-bridging complex with human arginase I., Org Biomol Chem
Eckert R et al., 2003, Zinc ions promote the interaction between heparin and heparin cofactor II., FEBS Lett
Herwald H et al., 2001, Zinc-dependent conformational changes in domain D5 of high molecular mass kininogen modulate contact activation., Eur J Biochem
Gantt SL et al., 2006, Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion., Biochemistry
Huus K et al., 2006, Chemical and thermal stability of insulin: effects of zinc and ligand binding to the insulin zinc-hexamer., Pharm Res
Ignjatovic T et al., 2002, Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor., J Biol Chem
Lokshin M et al., 2007, p53 and p73 display common and distinct requirements for sequence specific binding to DNA., Nucleic Acids Res

Version: 5.1.7

Version: 5.1.7

Version: 5.1.7

DrugBank: DB11136
- Version: 5.1.7
Alternate Names:

Mineral Support Drug Brand

Mineralex Drug Brand

Mte 4 Inj Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories cell-mediated immunity

Publications:

Jannetto PJ et al., 2001, Cytochrome b(5) plays a key role in human microsomal chromium(VI) reduction., Toxicology
TEND: METHYLDOPA
- Version: 01-August-2011
Alternate Names:

Drug Info:

Drug Class antihypertensive agents

Year of Approval 1962

Publications:
TdgClinicalTrial: METHYLDOPA
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antihypertensive Agents

Drug Class small molecule

FDA Approval 1962

Publications:
DTC: METHYLDOPA
- Version: 02-September-2020
Alternate Names:

CHEMBL459 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
TTD: Methyldopa
- Version: 2020.06.01
Alternate Names:

D0BA6T TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL459
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL459
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
PharmGKB: Methyldopa
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Adrenergic receptor alpha-2 agonist
Direct Interaction	yes

Trial Name	-
Novel drug target	Established target
Mechanism of Interaction	Adrenergic receptor alpha-2 agonist

555-30-6	CAS Number
Aldomet	Drug Brand
Aldomet Ester HCl Inj	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	adrenergic agents

ZINC	DrugBank Drug Name
7440-66-6	CAS Number
24 Multivitamins + Minerals	Drug Brand

MANGANESE	DrugBank Drug Name
7439-96-5	CAS Number
24 Multivitamins + Minerals	Drug Brand

Mineral Support	Drug Brand
Mineralex	Drug Brand
Mte 4 Inj	Drug Brand

METHYLDOPA Drug Record

METHYLDOPA chembl:CHEMBL459 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Adrenergic receptor alpha-2 agonist Direct Interaction yes

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Adrenergic receptor alpha-2 agonist Direct Interaction yes

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Adrenergic receptor alpha-2 agonist

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: SOURKES, 1954, Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine., Arch. Biochem. Biophys.

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Mayer MC et al., 2014, Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization., J Biol Chem

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Mayer MC et al., 2014, Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization., J Biol Chem

Interaction Types & Directionality: substrate

Interaction Info:

Publications: Jannetto PJ et al., 2001, Cytochrome b(5) plays a key role in human microsomal chromium(VI) reduction., Toxicology

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Bhuiyan MP et al., 2006, Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases., Bioorg Med Chem

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Payne JC et al., 2003, Spectroscopic determination of the binding affinity of zinc to the DNA-binding domains of nuclear hormone receptors., Biochemistry

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Bhuiyan MP et al., 2006, Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases., Bioorg Med Chem

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Mayer MC et al., 2014, Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization., J Biol Chem

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Kothinti R et al., 2010, Zinc finger transcription factor Zn3-Sp1 reactions with Cd2+., Chem Res Toxicol

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Gantt SL et al., 2006, Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion., Biochemistry

Interaction Types & Directionality: cofactor (activating)

Interaction Info:

Publications: Lokshin M et al., 2007, p53 and p73 display common and distinct requirements for sequence specific binding to DNA., Nucleic Acids Res

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Zeqiraj E et al., 2015, Higher-Order Assembly of BRCC36-KIAA0157 Is Required for DUB Activity and Biological Function., Mol Cell

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Krishnan U et al., 2006, Novel mutations that enhance or repress the aggregation potential of SOD1., Mol Cell Biochem

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Blom AM et al., 2003, Effects of zinc on factor I cofactor activity of C4b-binding protein and factor H., Arch Biochem Biophys

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Adrenergic receptor alpha-2 agonist

Direct Interaction yes

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Adrenergic receptor alpha-2 agonist

Direct Interaction yes

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Adrenergic receptor alpha-2 agonist

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

SOURKES, 1954, Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine., Arch. Biochem. Biophys.

Interaction Types & Directionality:

cofactor (activating)

Publications:

Mayer MC et al., 2014, Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization., J Biol Chem

Interaction Types & Directionality:

cofactor (activating)

Publications:

Mayer MC et al., 2014, Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization., J Biol Chem

Interaction Types & Directionality:

substrate

Publications:

Jannetto PJ et al., 2001, Cytochrome b(5) plays a key role in human microsomal chromium(VI) reduction., Toxicology

Interaction Types & Directionality:

cofactor (activating)

Publications:

Bhuiyan MP et al., 2006, Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases., Bioorg Med Chem

Interaction Types & Directionality:

cofactor (activating)

Interaction Types & Directionality:

cofactor (activating)

Publications:

Payne JC et al., 2003, Spectroscopic determination of the binding affinity of zinc to the DNA-binding domains of nuclear hormone receptors., Biochemistry

Interaction Types & Directionality:

cofactor (activating)

Publications:

Bhuiyan MP et al., 2006, Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases., Bioorg Med Chem

Interaction Types & Directionality:

cofactor (activating)

Publications:

Mayer MC et al., 2014, Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization., J Biol Chem

Interaction Types & Directionality:

cofactor (activating)

Publications:

Kothinti R et al., 2010, Zinc finger transcription factor Zn3-Sp1 reactions with Cd2+., Chem Res Toxicol

Interaction Types & Directionality:

cofactor (activating)

Publications:

Gantt SL et al., 2006, Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion., Biochemistry

Interaction Types & Directionality:

cofactor (activating)

Publications:

Lokshin M et al., 2007, p53 and p73 display common and distinct requirements for sequence specific binding to DNA., Nucleic Acids Res

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Zeqiraj E et al., 2015, Higher-Order Assembly of BRCC36-KIAA0157 Is Required for DUB Activity and Biological Function., Mol Cell

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Krishnan U et al., 2006, Novel mutations that enhance or repress the aggregation potential of SOD1., Mol Cell Biochem

Interaction Types & Directionality:

n/a

Publications:

Blom AM et al., 2003, Effects of zinc on factor I cofactor activity of C4b-binding protein and factor H., Arch Biochem Biophys

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Song C et al., 2013, Crystal structure and functional mechanism of a human antimicrobial membrane channel., Proc Natl Acad Sci U S A

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Marx G, 1988, Zinc binding to fibrinogen and fibrin., Arch Biochem Biophys

Interaction Types & Directionality:

n/a

Publications:

She YM et al., 2003, Identification of metal-binding proteins in human hepatoma lines by immobilized metal affinity chromatography and mass spectrometry., Mol Cell Proteomics

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

Interaction Types & Directionality:

n/a

Publications:

Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci